In the US, Ambrisentan (ambrisentan systemic) is a member of the drug class agents for pulmonary hypertension and is used to treat Pulmonary Arterial Hypertension.
US matches:
- Ambrisentan
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
C02KX02
CAS registry number (Chemical Abstracts Service)
0177036-94-1
Chemical Formula
C22-H22-N2-O4
Molecular Weight
378
Therapeutic Categories
Antihypertensive agent
Vasoconstrictor
Endothelin antagonist
Chemical Name
(+)-(2S)-2-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid (WHO)
Foreign Names
- Ambrisentanum (Latin)
- Ambrisentan (German)
- Ambrisentan (French)
- Ambrisentán (Spanish)
Generic Names
- Ambrisentan (OS: BAN)
- BSF 208075 (IS)
- LU 208075 (IS)
Brand Names
- Letairis
Gilead, United States - Volibris
Glaxo Group, Austria; Glaxo SmithKline, Spain; GlaxoGroup, Netherlands; GlaxoSmithKline, Canada; GlaxoSmithKline, Switzerland; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, United Kingdom; GlaxoSmithKline, Norway; GlaxoSmithKline, Sweden
International Drug Name Search
Glossary
BAN | British Approved Name |
IS | Inofficial Synonym |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
WHO | World Health Organization |
Click for further information on drug naming conventions and International Nonproprietary Names.